AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Nov 12, 2019--
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual Healthcare Conference in New York City.
AtriCure’s management is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191112005170/en/
CONTACT: Andy Wade
Senior Vice President and Chief Financial Officer
firstname.lastname@example.orgLynn Pieper Lewis
KEYWORD: NEW YORK OHIO UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: CARDIOLOGY MEDICAL SUPPLIES SURGERY HEALTH MEDICAL DEVICES HOSPITALS CLINICAL TRIALS OTHER HEALTH
SOURCE: AtriCure, Inc.
Copyright Business Wire 2019.
PUB: 11/12/2019 08:00 AM/DISC: 11/12/2019 08:01 AM